A Goldman Sachs analyst took CVS Caremark Corp shares off a list of recommended stocks Wednesday following a recovery in the drugstore chain's stock price John Heinbockel took the stock off Goldman's Americas Conviction Buy List, which contains stocks with the strongest "Buy" rating He still has a "Buy" rating on shares of the Woonsocket, RI, company CVS Caremark shares dropped 20 percent on Nov 5 after the company reported billions of dollars in contract losses for its Caremark pharmacy benefits management unit 
Share:  A Goldman Sachs analyst took <span class="company">CVS Caremark</span> Corp shares off a list of recommended stocks Wednesday following a recovery in the drugstore chain's stock price<span class="sent"> <span class="analyst">John Heinbockel</span> took the stock off Goldman's Americas Conviction Buy List, which contains stocks with the strongest "Buy" rating</span> He still has a "Buy" rating on shares of the Woonsocket, RI, company <span class="company">CVS Caremark</span> shares dropped 20 percent on Nov 5 after the company reported billions of dollars in contract losses for its Caremark pharmacy benefits management unit Tweet this 

"The third quarter's performance is a clear sign that the company is more likely to be rational when it comes to price investments and attempt to protect near term earnings," Goldman Sachs analyst John Heinbockel said in a note Jefferies analyst Scott Mushkin said a pricing survey he did in Philadelphia and Boston showed Supervalu's prices "creeping up" "This is, in turn, leading to accelerating market share losses, but better (operating) earnings in the short run," Mushkin said "They have got to walk that fine line between promoting just enough to get the customers in the store versus lowering prices too much," Doug Conn, a credit analyst with Hexagon Securities said 
Share:  <span class="sent">"The third quarter's performance is a clear sign that the company is more likely to be rational when it comes to price investments and attempt to protect near term earnings," Goldman Sachs analyst <span class="analyst">John Heinbockel</span> said in a note</span> Jefferies analyst Scott Mushkin said a pricing survey he did in Philadelphia and Boston showed <span class="company">Supervalu</span>'s prices "creeping up" "This is, in turn, leading to accelerating market share losses, but better (operating) earnings in the short run," Mushkin said "They have got to walk that fine line between promoting just enough to get the customers in the store versus lowering prices too much," Doug Conn, a credit analyst with Hexagon Securities said Tweet this 

Susan Anderson , Citigroup. John Heinbockel , Goldman Sachs. Simeon Gutman , Canaccord Adams.  
Share:  Susan Anderson , Citigroup. <span class="sent"><span class="analyst">John Heinbockel</span> , Goldman Sachs. Simeon Gutman , Canaccord Adams. </span> Tweet this 

Debra Weinswig , Citigroup. John Heinbockel , Goldman Sachs. Edward Kelly , Credit Suisse.  
Share:  Debra Weinswig , Citigroup. <span class="sent"><span class="analyst">John Heinbockel</span> , Goldman Sachs. Edward Kelly , Credit Suisse. </span> Tweet this 

The company is also looking for ways to reduce its debt. Earlier this month Rite Aid said it plans to , due in 2016, as part of a refinancing plan. If the refinancing is a success it would leave flailing Rite Aid debt free until 2012. Goldman Sachs analyst John Heinbockel said the company is completing its 2010 refinancing well ahead of expectations due to a more favorable credit market, and "growing confidence in the company's turnaround efforts." Looking forward, Rite Aid expects a full year loss of between 26 cents and 53 cents a share. 
Share:  The company is also looking for ways to reduce its debt. Earlier this month <span class="company">Rite Aid</span> said it plans to , due in 2016, as part of a refinancing plan. If the refinancing is a success it would leave flailing <span class="company">Rite Aid</span> debt free until 2012. <span class="sent"> Goldman Sachs analyst <span class="analyst">John Heinbockel</span> said the company is completing its 2010 refinancing well ahead of expectations due to a more favorable credit market, and "growing confidence in the company's turnaround efforts." </span> Looking forward, <span class="company">Rite Aid</span> expects a full year loss of between 26 cents and 53 cents a share. ...Earlier this month <span class="company">Rite Aid</span> said it plans to , due in 2016, as part of a refinancing plan. If the refinancing is a success it would leave flailing <span class="company">Rite Aid</span> debt free until 2012. <span class="sent"> Goldman Sachs analyst <span class="analyst">John Heinbockel</span> said the company is completing its 2010 refinancing well ahead of expectations due to a more favorable credit market, and "growing confidence in the company's turnaround efforts." </span> Looking forward, <span class="company">Rite Aid</span> expects a full year loss of between 26 cents and 53 cents a share. Revenue is estimated at $26.3 billion to $26.7 billion, while same store sales should rise in the range of .5% to 2.5%. Tweet this 

BY THE NUMBERS: Analysts polled by Thomson Reuters expect a loss of 13 cents per share and $6.55 billion in revenue. ANALYST TAKE: Rite Aid is working to reduce its debt, and earlier this month, it announced plans to offer $400 million in senior secured notes due 2016 as part of a refinancing plan. Goldman Sachs ( GS , news , people ) analyst John Heinbockel said the company is completing its 2010 refinancing well ahead of expectations due to a more favorable credit market, and "growing confidence in the company's turnaround efforts." . He said the company has nearly eliminated any refinancing risk until , which has helped Rite Aid shares rise in recent weeks. WHAT'S AHEAD: In April, Rite Aid said it expects to lose between $210 million and $435 million in fiscal 2010, which ends next Feb. 28. 
Share:  BY THE NUMBERS: Analysts polled by Thomson Reuters expect a loss of 13 cents per share and $6.55 billion in revenue. ANALYST TAKE: <span class="company">Rite Aid</span> is working to reduce its debt, and earlier this month, it announced plans to offer $400 million in senior secured notes due 2016 as part of a refinancing plan. <span class="sent"> Goldman Sachs ( GS , news , people ) analyst <span class="analyst">John Heinbockel</span> said the company is completing its 2010 refinancing well ahead of expectations due to a more favorable credit market, and "growing confidence in the company's turnaround efforts." . </span> He said the company has nearly eliminated any refinancing risk until , which has helped <span class="company">Rite Aid</span> shares rise in recent weeks. WHAT'S AHEAD: In April, <span class="company">Rite Aid</span> said it expects to lose between $210 million and $435 million in fiscal 2010, which ends next Feb. 28. ...BY THE NUMBERS: Analysts polled by Thomson Reuters expect a loss of 13 cents per share and $6.55 billion in revenue. ANALYST TAKE: <span class="company">Rite Aid</span> is working to reduce its debt, and earlier this month, it announced plans to offer $400 million in senior secured notes due 2016 as part of a refinancing plan. <span class="sent"> Goldman Sachs ( GS , news , people ) analyst <span class="analyst">John Heinbockel</span> said the company is completing its 2010 refinancing well ahead of expectations due to a more favorable credit market, and "growing confidence in the company's turnaround efforts." . </spa Tweet this 

Shares of CVS Caremark Corp rose Tuesday after a Goldman Sachs analyst put the stock on a list of recommended securities, saying several items should lift the company's share price over the next few months. John Heinbockel placed the stock on Goldman's "Conviction Buy List." He thinks the stock will rise to $34 over the next year. The drugstore operator and pharmacy benefits manager is scheduled to report its first quarter results May 5, and the following week, it will hold an analyst meeting. 
Share:  Shares of <span class="company">CVS Caremark Corp</span> rose Tuesday after a Goldman Sachs analyst put the stock on a list of recommended securities, saying several items should lift the company's share price over the next few months. <span class="sent"> <span class="analyst">John Heinbockel</span> placed the stock on Goldman's "Conviction Buy List." He thinks the stock will rise to $34 over the next year. </span> The drugstore operator and pharmacy benefits manager is scheduled to report its first quarter results May 5, and the following week, it will hold an analyst meeting. Tweet this